Ashwin Mali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ashwin Mali has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
C. Bothiraja
Department of Pharmaceutics, Goa College of Pharmacy, Goa University, Panaji, India
4 shared publicationsAtmaram Pawar
Department of Industrial Pharmacy, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to Be University), Pune, India
3 shared publicationsBothiraja Chellampillai
Department of Pharmaceutics, Goa College of Pharmacy, Goa University, Panaji, India
3 shared publicationsVaibhav Shinde
Department of Pharmacognosy, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Pune, India
3 shared publicationsVijaykumar Kuvar
Biological E. Limited, Hyderabad, India
3 shared publications- Vishin Ashish Patil
Department of Pharmaceutics, Bharati Vidyapeeth Deemed to be University, Poona College of Pharmacy, Pune, Maharashtra,411038, India
3 shared publications
Latest Publications
- 28 October 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Drug Delivery and Formulation
- Vol. 20
SNEDDS and Cubosome as Advanced Lipid Nanocarriers for Natural Anticancer Bioactives: Mechanistic Insights, Challenges and Future Perspectives
Introduction: Natural bioactive compounds have great potential as anticancer agents. However, their clinical use, including curcumin, resveratrol, and thymoquinone, is limited due to poor solubility, instability, and low oral bioavailability. The goal of this review is to examine the impact of advanced lipid-based nanocarriers, especially self-nanoemulsifying drug delivery systems (SNEDDS) and cubosomes, on the enhancement of the bioavailability and anticancer activity of natural bioactive compounds. Methods: This review was conducted using a structured search strategy across databases. Original research articles, preclinical (in vitro/in vivo) studies, and peer-reviewed reviews reporting formulation, pharmacokinetic, and anticancer efficacy data for SNEDDS- or cubosome-based delivery of natural bioactive compounds were included. Results: This review indicates that SNEDDS enhance drug solubilization, intestinal absorption, and lymphatic transport, whereas cubosomes, owing to their unique bicontinuous cubic structure, enable higher drug-loading capacity, controlled release, and targeted drug delivery. Discussion: Both nanocarrier systems improve pharmacokinetic profiles, enhance intracellular drug delivery, and may help to overcome multidrug resistance, thereby improving the therapeutic efficacy of natural anticancer bioactive compounds. Emerging approaches like AI-assisted formulation design and lipidomic-guided optimization further support the development of more effective lipid-based delivery systems. Conclusion: SNEDDS and cubosomes are promising lipid-based nanocarriers that can effectively address the limitations of natural anticancer bioactive compounds by enhancing solubility, bioavailability, and therapeutic performance. The encouraging preclinical evidence supports their potential in cancer therapy. Further pharmacokinetic, safety, and well-designed clinical studies are required to facilitate their successful clinical translation.
- 28 October 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Drug Delivery and Formulation
- Vol. 20
SNEDDS and Cubosome as Advanced Lipid Nanocarriers for Natural Anticancer Bioactives: Mechanistic Insights, Challenges and Future Perspectives
Introduction: Natural bioactive compounds have great potential as anticancer agents. However, their clinical use, including curcumin, resveratrol, and thymoquinone, is limited due to poor solubility, instability, and low oral bioavailability. The goal of this review is to examine the impact of advanced lipid-based nanocarriers, especially self-nanoemulsifying drug delivery systems (SNEDDS) and cubosomes, on the enhancement of the bioavailability and anticancer activity of natural bioactive compounds. Methods: This review was conducted using a structured search strategy across databases. Original research articles, preclinical (in vitro/in vivo) studies, and peer-reviewed reviews reporting formulation, pharmacokinetic, and anticancer efficacy data for SNEDDS- or cubosome-based delivery of natural bioactive compounds were included. Results: This review indicates that SNEDDS enhance drug solubilization, intestinal absorption, and lymphatic transport, whereas cubosomes, owing to their unique bicontinuous cubic structure, enable higher drug-loading capacity, controlled release, and targeted drug delivery. Discussion: Both nanocarrier systems improve pharmacokinetic profiles, enhance intracellular drug delivery, and may help to overcome multidrug resistance, thereby improving the therapeutic efficacy of natural anticancer bioactive compounds. Emerging approaches like AI-assisted formulation design and lipidomic-guided optimization further support the development of more effective lipid-based delivery systems. Conclusion: SNEDDS and cubosomes are promising lipid-based nanocarriers that can effectively address the limitations of natural anticancer bioactive compounds by enhancing solubility, bioavailability, and therapeutic performance. The encouraging preclinical evidence supports their potential in cancer therapy. Further pharmacokinetic, safety, and well-designed clinical studies are required to facilitate their successful clinical translation.
- 6 March 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (3) , 264
QbD-Guided RP-HPLC Method for Luteolin Featuring Full Factorial Design and Response Surface Optimization
- 6 March 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (3) , 264
QbD-Guided RP-HPLC Method for Luteolin Featuring Full Factorial Design and Response Surface Optimization
- 27 January 2026
- Published by Springer Nature in Progress in Additive Manufacturing
- Vol. 11 (4) , 3227-3244
Development of 3D-printed taste-masked extended-release tablet of Bacopa monnieri with HME-FDM technique: in vitro and in vivo study
- 27 January 2026
- Published by Springer Nature in Progress in Additive Manufacturing
- Vol. 11 (4) , 3227-3244
Development of 3D-printed taste-masked extended-release tablet of Bacopa monnieri with HME-FDM technique: in vitro and in vivo study
- 12 May 2025
- Published by Springer Nature in Biomedical Materials & Devices
- Vol. 4 (2) , 1516-1547
Exploring the Albumin Nanoparticles as the Next-Generation Advanced Multifunctional Biomaterials for Inhalation Lung Therapy: Facts, Prospects, and Challenges
- 12 May 2025
- Published by Springer Nature in Biomedical Materials & Devices
- Vol. 4 (2) , 1516-1547
Exploring the Albumin Nanoparticles as the Next-Generation Advanced Multifunctional Biomaterials for Inhalation Lung Therapy: Facts, Prospects, and Challenges
- Open Access
- 9 August 2024
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 12 (4) , 687-702
Investigation of magnesium aluminometasilicate (Neusilin US2) based surface solid dispersion of sorafenib tosylate using QbD approach: In vitro and in vivo pharmacokinetic study
Background and purpose: Sorafenib tosylate (SFN), a potent multikinase inhibitor, is used for the treatment of various cancers. However, it shows limited therapeutic applications due to its poor biopharmaceutical properties. The aim of the present investigation is to develop surface solid dispersion (SSD) of SFN using adsorbent to improve its solubility, bioavailability and therapeutic efficacy. Experimental approach: The SFN-SSD was prepared by modified solvent evaporation technique using Neusilin US2 (magnesium aluminometasilicate) as an adsorbent and sodium dodecyl sulphate as a surfactant. SFN-SSD was optimized by adopting the design of experiment (DOE) using 32 factorial designs and characterized in terms of in-vitro and in-vivo efficacy. Key results: The obtained SFN-SSD showed more than 20-fold improvement in SFN solubility. The FTIR depicted hydrogen bonding between SFN and Neusilin. Further, PXRD and DSC indicated the molecular dispersion of SFN to be amorphous. SFN-SSD and SFN immediate release tablets reflected cumulative release of 97.13 and 29.93 % in 1 h. The pharmacokinetics study of SFN-SSD showed 2 and 6.5-fold improvement in maximum concentration (Cmax,) and area under the curve (AUC0-t) as compared to pure SFN due to faster drug release at the absorption site. Conclusion: The study concluded that the SSD could be a scalable formulation approach and more industry-friendly technology to improve the biopharmaceutical properties of SFN.
- 9 August 2024
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 12 (4) , 687-702
Open AccessInvestigation of magnesium aluminometasilicate (Neusilin US2) based surface solid dispersion of sorafenib tosylate using QbD approach: In vitro and in vivo pharmacokinetic study
Background and purpose: Sorafenib tosylate (SFN), a potent multikinase inhibitor, is used for the treatment of various cancers. However, it shows limited therapeutic applications due to its poor biopharmaceutical properties. The aim of the present investigation is to develop surface solid dispersion (SSD) of SFN using adsorbent to improve its solubility, bioavailability and therapeutic efficacy. Experimental approach: The SFN-SSD was prepared by modified solvent evaporation technique using Neusilin US2 (magnesium aluminometasilicate) as an adsorbent and sodium dodecyl sulphate as a surfactant. SFN-SSD was optimized by adopting the design of experiment (DOE) using 32 factorial designs and characterized in terms of in-vitro and in-vivo efficacy. Key results: The obtained SFN-SSD showed more than 20-fold improvement in SFN solubility. The FTIR depicted hydrogen bonding between SFN and Neusilin. Further, PXRD and DSC indicated the molecular dispersion of SFN to be amorphous. SFN-SSD and SFN immediate release tablets reflected cumulative release of 97.13 and 29.93 % in 1 h. The pharmacokinetics study of SFN-SSD showed 2 and 6.5-fold improvement in maximum concentration (Cmax,) and area under the curve (AUC0-t) as compared to pure SFN due to faster drug release at the absorption site. Conclusion: The study concluded that the SSD could be a scalable formulation approach and more industry-friendly technology to improve the biopharmaceutical properties of SFN.
- 27 June 2024
- Published by Springer Nature in BioNanoScience
- Vol. 14 (3) , 3341-3354
Exploring the Potential of Three-Layered Self-assembled Biomaterial-Based Dry Powder Inhaler for Enhanced Structural Integrity and Lung Deposition of Bioactive Lysozyme
- 27 June 2024
- Published by Springer Nature in BioNanoScience
- Vol. 14 (3) , 3341-3354
Exploring the Potential of Three-Layered Self-assembled Biomaterial-Based Dry Powder Inhaler for Enhanced Structural Integrity and Lung Deposition of Bioactive Lysozyme
- Open Access
- 19 January 2024
- Published by Springer Nature in Research Square
Exploring the potential of three-layered self-assembled biomaterial-based dry powder inhaler for enhanced structural integrity and lung deposition of bioactive Lysozyme
Aquasome (AQ) is one of the most recently developed self-assembled novel nanocarrier systems that is predominantly effective due to its property of maintaining the structural integrity of proteins, peptides, and delicate bioactive molecules. The objective of the present study was to investigate the feasibility of AQ as a carrier for dry powder inhalers (DPI) to achieve enhanced aerosol performance for Lysozyme (LYS). The water-in-water emulsification method was explored to prepare AQ by using gelatin and cellobiose. The lyophilized LYS-loaded AQ-based dry powder inhaler (DPI) (AQ/LYS-DPI) was evaluated and compared with commercial form of DPI (C-DPI) for its physicochemical properties, in vitro lung deposition, circular dichroism (CD), haemolysis assay, and toxicity study. The developed AQ/LYS-DPI had a particle size of 104.3 ± 3.8 µm, drug loading of 88.70 ± 2.4, and zeta potential of -8.4 mV with sustained release up to 18 h. The mass median aerodynamic diameter (MMAD) and fine particle fraction (FPF) of AQ/LYS-DPI were found to be 2.43 ± 0.27 µm and 61.52 ± 0.38 %, respectively, reflecting enhanced lung deposition. The CD, hemolytic activity, and toxicity study revealed better structural integrity and biocompatibility with no signs of inflammation or toxicity in the formulation. It was observed that the developed AQ/LYS-DPI effectively controls the structural integrity of lysozyme and can be explored as a novel carrier for pulmonary administration of bioactive molecules.
- 19 January 2024
- Published by Springer Nature in Research Square
Open AccessExploring the potential of three-layered self-assembled biomaterial-based dry powder inhaler for enhanced structural integrity and lung deposition of bioactive Lysozyme
Aquasome (AQ) is one of the most recently developed self-assembled novel nanocarrier systems that is predominantly effective due to its property of maintaining the structural integrity of proteins, peptides, and delicate bioactive molecules. The objective of the present study was to investigate the feasibility of AQ as a carrier for dry powder inhalers (DPI) to achieve enhanced aerosol performance for Lysozyme (LYS). The water-in-water emulsification method was explored to prepare AQ by using gelatin and cellobiose. The lyophilized LYS-loaded AQ-based dry powder inhaler (DPI) (AQ/LYS-DPI) was evaluated and compared with commercial form of DPI (C-DPI) for its physicochemical properties, in vitro lung deposition, circular dichroism (CD), haemolysis assay, and toxicity study. The developed AQ/LYS-DPI had a particle size of 104.3 ± 3.8 µm, drug loading of 88.70 ± 2.4, and zeta potential of -8.4 mV with sustained release up to 18 h. The mass median aerodynamic diameter (MMAD) and fine particle fraction (FPF) of AQ/LYS-DPI were found to be 2.43 ± 0.27 µm and 61.52 ± 0.38 %, respectively, reflecting enhanced lung deposition. The CD, hemolytic activity, and toxicity study revealed better structural integrity and biocompatibility with no signs of inflammation or toxicity in the formulation. It was observed that the developed AQ/LYS-DPI effectively controls the structural integrity of lysozyme and can be explored as a novel carrier for pulmonary administration of bioactive molecules.